Evidence map›Paper›PMID 41665753›Full record

ReviewDiscover oncology2026

Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.

Zhihao Luo, Qian Hu, Meng Ren, Li Wang, Qingshuang Zou, Xiaosha Wen, Shang Chen, Quan Liu, Dixian Luo, Zifen Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhihao LuoInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China.
Qian HuInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China.
Meng RenSchool of Nursing, University of South China, Hengyang, Hunan Province, P. R. China.
Li WangInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China.
Qingshuang ZouLaboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen University, Shenzhen, Guangdong Province, P. R. China.
Xiaosha WenLaboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen University, Shenzhen, Guangdong Province, P. R. China.
Shang ChenHunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, 410219, China.
Quan LiuLaboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen University, Shenzhen, Guangdong Province, P. R. China.
Dixian LuoLaboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen University, Shenzhen, Guangdong Province, P. R. China.
Zifen GuoInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China. guozifen76@163.com.

Funding

General Projects of the National Natural Science Foundation of China 82273236Guangdong Provincial Clinical Research Center for Laboratory Medicine 2023B110008National Key R&D Program of China 2023YFA0915602Newly introduced discipline leader fund project in Nanshan District of Shenzhen City NSZD2023020Shenzhen Natural Science Foundation Project JCYJ20240813114502004
6 · The paper itself

Abstract

CAR-T cell therapy, which genetically modifies a patient’s T cells to express chimeric antigen receptors (CARs), has shown remarkable efficacy in treating blood cancers. However, its application to solid tumors is hindered by challenges such as inadequate tumor infiltration, an immunosuppressive microenvironment, and metabolic obstacles. This review explores potential targets for CAR-T cells in solid tumors and examines innovative strategies to enhance their tumor penetration, survival, and cytotoxicity. These include advanced CAR designs, combination therapies, and methods to improve CAR-T cell function amidst metabolic competition. As research and technology progress, CAR-T therapy holds promise as a viable option for solid tumor treatment, with future efforts emphasizing interdisciplinary collaboration to unlock its full potential.

Indexed as

Antigen escapeCAR-TImmunosuppressive microenvironmentImmunotherapyMetabolic competitionSolid tumor

Identifiers

PMID41665753
PMCPMC12891316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.